AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...
AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...
AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...
Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
The probe conducted by China regulators, which reportedly centers on allegations that AstraZeneca employees improperly imported cancer medications like Enhertu and Imjudo from Hong Kong into ...
AstraZeneca PLC (NASDAQ ... growth outlook driven by indication expansion for current products (Tagrisso and Enhertu) as well as a range of pipeline assets.” AstraZeneca PLC (NASDAQ:AZN) is ...